>
Medadvisor logo

MDR - Medadvisor Share Price

A$0.295 0.0  1.7%

Last Trade - 14/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £58.3m
Enterprise Value £51.9m
Revenue £10.8m
Position in Universe 857th / 1911
Bullish
Bearish
Unlock MDR Revenue
Momentum
Relative Strength (%)
1m -15.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -55.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1.40 1.76 4.90 7.39 9.19 11.1 +51.1%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020,Medadvisor Ltd revenues increased from A$4.5M to A$13.1M.Net loss increased 48% to A$7.8M. Revenues reflect USAOperations segment increase from A$0K to A$8M, MedAdvisorsegment increase of 13% to A$5.1M. Higher net loss reflectsEmployee benefits expenses - Balancing increase of 75% toA$9.2M (expense), Other Expenses increase from A$889K toA$2.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

MDR Revenue Unlock MDR Revenue

Net Income

MDR Net Income Unlock MDR Revenue

Normalised EPS

MDR Normalised EPS Unlock MDR Revenue

PE Ratio Range

MDR PE Ratio Range Unlock MDR Revenue

Dividend Yield Range

MDR Dividend Yield Range Unlock MDR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
MDR EPS Forecasts Unlock MDR Revenue
Profile Summary

MedAdvisor Limited, formerly Exalt Resources Limited, is a digital medication management company. The Company is engaged in the development and deployment of the MedAdvisor medication and adherence platform. Its platform is focused on improving health outcomes by connecting health professionals with their patients using mobile and Web technologies. The Company's segments include MedAdvisor, which includes the business activities of the MedAdvisor medication management adherence platform and Corporate. The MedAdvisor platform features include Automatic Medication List, Fill-My-Scripts and See-My-Doctor, Take-My-Meds and Tap-To-Refill. Its home screen provides an automatic list of all patient prescription medications, updated whenever patient fill scripts. The Take-My-Meds feature lets user's smartphone or tablet alert them every time they are due to take medication. Its Tap To Refill feature allows patients to order prescription repeats to be dispensed in advance at their pharmacy.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated July 21, 2010
Public Since May 26, 2011
No. of Shareholders: 2,744
No. of Employees: 100
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 359,477,166
Free Float (0.0%)
Eligible for
ISAs
SIPPs
MDR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for MDR
Upcoming Events for MDR
Frequently Asked Questions for Medadvisor
What is the Medadvisor share price?

As of 14/05/21, shares in Medadvisor are trading at A$0.295, giving the company a market capitalisation of £58.3m. This share price information is delayed by 15 minutes.

How has the Medadvisor share price performed this year?

Shares in Medadvisor are currently trading at A$0.295 and the price has moved by -44.58% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Medadvisor price has moved by -58.52% over the past year.

What are the analyst and broker recommendations for Medadvisor?

There are no analysts currently covering Medadvisor.

When will Medadvisor next release its financial results?

Medadvisor is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Medadvisor dividend yield?

Medadvisor does not currently pay a dividend.

Does Medadvisor pay a dividend?

Medadvisor does not currently pay a dividend.

When does Medadvisor next pay dividends?

Medadvisor does not currently pay a dividend.

How do I buy Medadvisor shares?

To buy shares in Medadvisor you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Medadvisor?

Shares in Medadvisor are currently trading at A$0.295, giving the company a market capitalisation of £58.3m.

Where are Medadvisor shares listed? Where are Medadvisor shares listed?

Here are the trading details for Medadvisor:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: MDR
What kind of share is Medadvisor?

Based on an overall assessment of its quality, value and momentum, Medadvisor is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Medadvisor share price forecast 2021?

We were not able to load any forecast data for Medadvisor.

How can I tell whether the Medadvisor share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medadvisor. Over the past six months, the relative strength of its shares against the market has been -34.34%. At the current price of A$0.295, shares in Medadvisor are trading at -24.22% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Medadvisor PE Ratio?

We were not able to find PE ratio data for Medadvisor.

Who are the key directors of Medadvisor?

Medadvisor's management team is headed by:

Robert Read - CEO
Josh Swinnerton - OTH
Jim Xenos - NED
Carlo Campiciano - SEC
Sandra Hook - NED
Simon Glover - CFO
Christopher Ridd - NEC
Steve Watt - OTH
Craig Schnuriger - CTO
Naomi Lawrie - GCN
Who are the major shareholders of Medadvisor?

Here are the top five shareholders of Medadvisor based on the size of their shareholding:

Perennial Value Management Ltd. Investment Advisor
Percentage owned: 11.27% (42.5m shares)
Health Management Systems, Inc. Corporation
Percentage owned: 8.33% (31.4m shares)
EBOS PH Pty. Ltd. Corporation
Percentage owned: 7.01% (26.5m shares)
Xenos (Jim) Individual Investor
Percentage owned: 5.46% (20.6m shares)
Jencay Capital Pty Ltd Investment Advisor
Percentage owned: 4.79% (18.1m shares)
Similar to MDR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.